Monte Rosa Therapeutics logo
Monte Rosa Therapeutics
GLUE | NASDAQ
Chart Builder DCF Calculator
$9.16
-$0.21 (-2.24%)
At close: Nov 16, 2026, 4:00 PM ET
$9.16
$0.00 (0.00%)
After-hours: Nov 16, 2026, 5:56 PM ET

Monte Rosa Therapeutics Company Profile

Company profile explained

Company Profile

Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.

Key Executives

Name Position
Markus Warmuth President, Chief Executive Officer & Director
Jennifer Champoux Chief Operating Officer
Magnus Walter DPHIL Chief Technology Officer
Andrew Funderburk Chief Investor Relations and Strategy Officer
Filip Janku Chief Medical Officer
John C. Castle Chief Data & Information Officer
Matthew Bowen Corporate Controller & Principal Accounting Officer
Phil Nickson Chief Business & Legal Officer
Sharon Townson Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 06, 2026 4 Filing
Oct 01, 2026 8-K Current Report
Sep 08, 2026 8-K Current Report
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 17, 2026 4 Filing
Jul 16, 2026 4 Filing
Jul 08, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Monte Rosa Therapeutics
Monte Rosa Therapeutics logo
Country United States
IPO Date Jun 24, 2021
Industry Biotechnology
Sector Healthcare
Employees 173
CEO Markus Warmuth

Contact Details

321 Harrison Avenue Boston, Massachusetts 02118 United States

Stock Details

Ticker Symbol GLUE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001826457
CUSIP Number 61225M102
ISIN Number US61225M1027
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.